Influenza Vaccines

Questions: Discounts, Updates etc.

Price: $7,600.00

Publication Date: 2005-12-26

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Influenza is a highly infectious disease which globally infects 10-20% of the population every year causing up to 500,000 deaths. Although all persons are at risk, the elderly and the young are the most vulnerable. For decades, trivalent prophylactic vaccines produced in chicken eggs have been used to reduce the burden of influenza with approximately 300 million doses produced globally.


Scope

  • Evaluation of total 2004 global vaccine market value, historical growth since 1999 and major company market share
  • Overview of major influenza vaccine products, producers and new product development
  • Expert led discussion of drivers and resistors to cell culture flu systems in seasonal/pandemic scenarios
  • Forecast value and demand (doses) for influenza vaccines in 2010 with launch predictions


    • Report Highlights
    Despite the Chiron debacle, collective sales of influenza vaccines from Western producers surpassed the $1 billion level in 2004 with 10% growth over the previous year. Expanding recommendations for vaccination continue to fuel global demand.

    Datamonitor forecasts that in the seven major markets demand for influenza vaccines will expand to 370 million doses and a market value of $3.7 billion by 2010. Global capacity will expand appropriately to meet this goal but competition will intensify with 11 predicted new product launches.

    Cell culture flu could amount to 15% of US doses supplied in 2010 if the FDA can overcome safety concerns with the MDCK line. Although heralded as a much needed solution, cell culture flu still requires substantial capital investment.


    Reasons to Purchase

  • Review an up to date expert discussion of major dynamics within the global vaccine market
  • Gain insight into how the market for influenza vaccines is now an attractive growth option
  • Understand commercial drivers and resistors for cell culture flu systems

    • Table of Contents

    Other users found this report page using the following search terms: influenza vaccine influenza vaccine market vaccines flu inflexal sales cons pros cell

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.